Investing.com - Cellectis (NASDAQ: CLLS) reported second quarter EPS of $-0.280, better than the analyst estimate of $-0.290. Revenue for the quarter came in at $9.5M versus the consensus estimate of $3.47M.
Cellectis's stock price closed at $2.07. It is down -32.350% in the last 3 months and up 11.890% in the last 12 months.
Cellectis saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Cellectis's stock price’s past reactions to earnings here.
According to InvestingPro, Cellectis's Financial Health score is "fair performance".
Check out Cellectis's recent earnings performance, and Cellectis's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar